 This study is aimed at evaluating the effects of intermittent hormonal treatment with complete androgen suppression Leuprorelin 3.75 milligram mg sustained release SR and Flutamide in patients presenting with stage D2 or Tx Nx M1 M1a metastatic prostrate cancer, with a prostate specific antigen PSA level 5-fold higher than normal PSA greater than or equal to 20 nanogram per milliliter ngmL, as quantitated by the Hybritech radioimmunoassay and with a subsequent decline to normal PSA less than 4 ngmL during the initial 6 months of induction treatment. The results will be compared with those obtained after continuous hormonal therapy with complete androgen suppression. 